

Attorney Docket No. 60005161-0168

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED  
CENTRAL FAX CENTER

In re Patent Application of: ) Group Art Unit: 1648  
Herbert W. Virgin ) Examiner: Stacy Brown Chen  
Application No. 10/757,832 )  
Filed: January 14, 2004 )  
For: MURINE CALICIVIRUS )

DEC 22 2005

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT  
BEFORE MAILING DATE OF EITHER A FINAL ACTION  
OR NOTICE OF ALLOWANCE (37 C.F.R. § 1.97(c))**

**SUBSTITUTE INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement transmitted herewith is being filed *after* three months of the filing date of this national application or the date of entry of the national stage as set forth in Section 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but *before* the mailing date of either a final action under Section 1.113 or a notice of allowance under Section 1.311, whichever occurs first.

This information disclosure statement will replace the information disclosure statement filed on December 23, 2004, by former counsel for Applicant. A copy of cite number 7 is enclosed. Copies of the remaining references were provided to the Office on December 23, 2004.

12/23/2005 TL0111 00000004 10757832  
01 FC:1806 180.00 OP

10/757,832 (60005161-0168)  
Transmittal of Information Disclosure Statement  
Page 2

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.


The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

Applicant submits a credit card payment form in the amount of \$180.00 to cover the fee set forth in 37 C.F.R. § 1.17(p) for submission of an information disclosure statement under § 1.97(c).

The Commissioner is hereby authorized to credit overpayments or to charge any deficiency in a required fee to Deposit Account No. 19-3140. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Dated: December 22, 2005

By: 

Saul L. Zackson, Ph.D.  
Registration No. 52,391  
SONNENSCHEIN NATH & ROSENTHAL  
P.O. Box 061080  
Wacker Drive Station, Sears Tower  
Chicago, Illinois 60606-1080  
(314) 259-5802

2318832.V-1

<b>Substitute for form 1449B/PTO</b>			<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			<b>Application Number</b>	10/757,632
<i>(use as many sheets as necessary)</i>			<b>Filing Date</b>	January 14, 2004
Sheet 1 of 1			<b>First Named Inventor</b>	Herbert W. Virgin
			<b>Art Unit</b>	1648
			<b>Examiner Name</b>	Stacy Brown Chen
			<b>Attorney Docket Number</b>	60005161-0168
<b>OTHER ITEMS – NON PATENT LITERATURE DOCUMENTS</b>				
Examiner Initials* <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	1	BALL et al., "Oral Immunization with Recombinant Norwalk Virus-Like Particles Induces a Systemic and Mucosal Immune Response in Mice," J. Virol., 1998, pp. 1345-1353, Vol. 72.		
	2	GEISSLER et al., "Feline Calicivirus Capsid Protein Expression and Capsid Assembly in Cultured Feline Cells," J. Virol., 1999, pp. 834-838, Vol. 73.		
	3	GREEN et al., "Comparison of the Reactivities of Baculovirus-Expressed Recombinant Norwalk Virus Capsid Antigen with Those of the Native Norwalk Virus Antigen in Serologic Assays and Some Epidemiologic Observations," J. Clin. Microbiol., 1993, pp. 2185-2191, Vol. 31.		
	4	GREEN et al., "Expression and Self-Assembly of Recombinant Capsid Protein from the Antigenically Distinct Hawaii Human Calivirus," J. Clin. Microbiol., 1997, pp. 1909-1914, Vol. 35.		
	5	GUERRERO et al., "Recombinant Norwalk Virus-Like Particles Administered Intranasally to Mice Induce Systemic and Mucosal (Fecal and Vaginal) Immune Responses," J. Virol., 2001, pp. 9713-9722, Vol. 75.		
	6	JIANG et al., "Baculovirus Expression and Antigenic Characterization of the Capsid Proteins of Three Norwalk-Like Virus," Archives of Virol., 2002, pp. 119-130, Vol. 147.		
	7	JIANG et al., "Expression, Self-Assembly, and Antigenicity of the Norwalk Virus Capsid Protein," J. Virol., 1992, pp. 6527-5532, Vol. 66.		
	8	LIANG et al., "Protection Against Fatal Sindbis Virus Encephalitis by Beclin, a Novel Bct-2-Interacting Protein," J. Virol., 1998, pp. 8586-8696, Vol. 72.		
	9	PELOSI et al., "The Seroepidemiology of Genogroup 1 and Genogroup 2 Norwalk-Like Viruses in Italy," J. Med. Virol., 1999, pp. 93-99, Vol. 58.		
	10	PRASAD et al., "Structural Studies of Recombinant Norwalk Capsids," J. Infect. Dis., 2000, pp. S317-S321, Vol. 181.		
	11	WHITE et al., "Attachment and Entry of Recombinant Norwalk Virus Capsids to Cultured Human and Animal Cell Lines," J. Virol., 1996, pp. 6589-6597, Vol. 70.		
Examiner Signature		Date Considered		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1540, Alexandria, VA 22213-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1540, Alexandria, VA 22213-1450.

If you need assistance in completing this form, call 1-800-PTO-9199.